Abstract | BACKGROUND: METHODS: RESULTS: Compared with patients with estimated glomerular filtration rates (eGFRs) ≥60 mL/min per 1.73 m2, stage III CKD patients (n = 1697; 30% of the cohort; mean eGFR 49 mL/min per 1.73 m2) were older (mean age 75 v 68 years) with more frequent hypertension, diabetes, heart failure, and previous stroke (all P < .01). Stage III CKD was an independent predictor of primary events (hazard ratio [HR] 1.6; P = .01) and major hemorrhage (HR 2.2; P = .02). Apixaban significantly reduced primary events by 68% (5.6% per year on aspirin v 1.8% per year on apixaban; HR 0.32; 95% confidence interval [CI] 0.18-0.55; P < .001) for stage III CKD participants and by 43% (2.8% per year on aspirin v 1.6% per year on apixaban; HR 0.57; 95% CI 0.37-0.87; P = .009) for patients with eGFRs ≥60 mL/min per 1.73 m2 (P for interaction = .10). There was no significant difference in major hemorrhage in stage III CKD patients by treatment: 2.2% per year with aspirin versus 2.5% per year with apixaban (HR 1.2; 95% CI 0.65-2.1). CONCLUSIONS:
|
Authors | John W Eikelboom, Stuart J Connolly, Peggy Gao, Ernesto Paolasso, Raffaele De Caterina, Steen Husted, Martin O'Donnell, Salim Yusuf, Robert G Hart |
Journal | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
(J Stroke Cerebrovasc Dis)
Vol. 21
Issue 6
Pg. 429-35
(Aug 2012)
ISSN: 1532-8511 [Electronic] United States |
PMID | 22818021
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 National Stroke Association. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers
- Fibrinolytic Agents
- Pyrazoles
- Pyridones
- apixaban
- Creatinine
- Aspirin
|
Topics |
- Aged
- Aspirin
(adverse effects, therapeutic use)
- Atrial Fibrillation
(complications, drug therapy)
- Biomarkers
(blood)
- Chi-Square Distribution
- Creatinine
(blood)
- Double-Blind Method
- Embolism
(etiology, prevention & control)
- Female
- Fibrinolytic Agents
(adverse effects, metabolism, therapeutic use)
- Glomerular Filtration Rate
- Hemorrhage
(chemically induced)
- Humans
- Kidney
(metabolism, physiopathology)
- Male
- Proportional Hazards Models
- Pyrazoles
(adverse effects, metabolism, therapeutic use)
- Pyridones
(adverse effects, metabolism, therapeutic use)
- Renal Insufficiency, Chronic
(blood, complications, diagnosis, physiopathology)
- Risk Assessment
- Risk Factors
- Severity of Illness Index
- Stroke
(etiology, prevention & control)
- Treatment Outcome
|